Oxamnichin

Gefahreninformationscode (GHS)

• Bildanzeige (GHS)

  

• Alarmwort

  Warnung

• Gefahrenhinweise

  H302：Gesundheitsschädlich bei Verschlucken.

  H413：Kann für Wasserorganismen schädlich sein, mit langfristiger Wirkung.

• Sicherheit

  P264：Nach Gebrauch gründlich waschen.

  P264：Nach Gebrauch gründlich waschen.

  P270：Bei Gebrauch nicht essen, trinken oder rauchen.

  P301+P312：BEI VERSCHLUCKEN: Bei Unwohlsein GIFTINFORMATIONSZENTRUM/Arzt/... (geeignete Stelle für medizinische Notfallversorgung vom Hersteller/Lieferanten anzugeben) anrufen.

  P330：Mund ausspülen.

  P501：Inhalt/Behälter ... (Entsorgungsvorschriften vom Hersteller anzugeben) zuführen.

OXAMNIQUINE(200MG)DISCONTINUED Chemische Eigenschaften,Einsatz,Produktion Methoden

• Beschreibung

  Oxamniquine was originally investigated in the 1960s and was found to have limited antiprotozoal activity, with activity against Schi stosoma mansoni but no activity against the other two schistosomal organisms. In addition, the drug is stage specific, with activity against cercariae and very young schistosomula and adult worms. For reasons that remain unknown, the drug is more effective against adult male worms than against female worms. The drug has structural similarity to hycanthone, which is no longer used because of severe toxicity and teratogenic effects.

• Originator

  Vansil, Pfizer , US ,1980

• Verwenden

  Antischistosomal.

• Definition

  ChEBI: A member of the class of quinolines that is 1,2,3,4-tetrahydroquinoline which is substituted at positions 2, 6, and 7 by (isopropylamino)methyl, hydroxymethyl, and nitro groups, respectively.

• Indications

  Oxamniquine (Vansil) is a tetrahydroquinoline that stimulates parasite muscular activity at low concentrations but causes paralysis at higher concentrations. The drug may act by esterification and binding of DNA, leading to the death of the schistosome by interruption of its nucleic acid and protein synthesis. The fluke may esterify oxamniquine to produce a reactive metabolite that alkylates parasite DNA. Resistance results from absent or defective esterifying activity of the drug. Oxamniquine has a restricted range of efficacy, being active only against S. mansoni infections.
  Oxamniquine is given orally and is readily absorbed from the intestinal tract. Peak concentrations in plasma are obtained in about 3 hours. The drug is excreted in urine mostly as a 6-carboxyl derivative.
  Side effects include CNS toxicity with unsteadiness and occasionally seizures, especially in patients with a history of seizures. It is contraindicated in pregnancy.

• Manufacturing Process

  (1) Four fermenters are set up, each one of which contained 2.0 liters of the following medium, sterilized for 35 minutes at 15 psi, respectively
  The fermenters are inoculated with 7.5% by volume of a 24-hour old culture of Aspergillus sclerotiorum Huber grown at 28°C in 50 ml aliquots of the above described soybean-glucose medium contained in 300 ml Erlenmeyer flasks, placed on a shaker rotating at approximately 230 rpm. The inoculated fermenters are agitated at 1,380 rpm and each aerated with 1 liter of air per minute and at a temperature of 28°C for 47 hours. A silicone antifoam is added when required. At the end of the 47 hour period, the pH of the fermentation broth rose to 6.8 to 6.9. Sulfuric acid is then added with sterile precautions to restore the pH to 6.5.
  (2) 0.75 g of 2-isopropylaminomethyl-6-methyl-7-nitro-1,2,3,4tetrahydroquinoline as hydrogen maleate, dissolved in 75 ml of sterile water, is added to each of the four fermenters and agitation and aeration are continued for a further 23 hours. The whole fermentation broths from each fermenter are pooled, the pH adjusted to 8.0 with sodium hydroxide and the 8.2 liters of fermentation broth thus obtained are extracted by agitating vigorously with 16.4 liters of methylene chloride for 10 minutes. The solvent extract is then dried over anhydrous sodium sulfate and subsequently evaporated to dryness at a temperature below 40°C (dry weight 5.567 g).
  (3) The dark brown residue from (2) is extracted four times with methanol at room temperature, decanting the solution from the insoluble material. The combined methanol extracts, total volume about 200 ml, are then filtered and treated with 3 g of sodium borohydride, added in portions over a period of 30 minutes with stirring, to reduce any 6-formyl compound present to the 6hydroxymethyl compound. The methanol solution is then allowed to stand overnight at room temperature and is thereafter diluted with 1 liter of ether. The solution is washed 4 times with 500 ml of water and the resulting pale yellow ethereal solution is dried over magnesium sulfate. The ether is next removed by vacuum distillation from a water bath at 40°C. The residue is dissolved in about 75 ml of isopropanol at 50°C, filtered to remove any insoluble particles and cooled overnight in the refrigerator. The product is collected and dried in vacuo to yield 0.5 g of 6-hydroxymethyl-2isopropylaminomethyl-7-nitro-1,2,3,4-tetrahydroquinoline as pale yellow crystals of melting point 147°C to 149°C. A further 0.5 g of crude material is obtained from the mother liquors of the recrystallization. Total yield is therefore 1.0 g (0.0036 mol) from 3.0 g (0.0079 mol) of starting material, i.e., 45% of the theoretical amount.

• Trademarks

  Vansil (Pfizer).

• Therapeutic Function

  Antischistosomal

• Antimicrobial activity

  Activity is restricted to Schistosoma mansoni. Some strains, particularly those in Egypt and Southern Africa, require higher doses for efficacy owing to innate tolerance.

• Pharmazeutische Anwendungen

  A synthetic quinolinemethanol, available for oral administration.

• Mechanism of action

  Oxamniquine is activated via esterification to a biological ester that spontaneously dissociates to an electrophile, which alkylates the helminth DNA, leading to irreversible inhibition of nucleic acid metabolism. Resistant helminths do not esterify oxamniquine; therefore, activation does not occur. Other metabolic reactions consist of oxidative reactions, leading to inactivation. The metabolites are excreted primarily in the urine.

• Pharmakokinetik

  It is rapidly absorbed after oral administration, achieving a peak concentration of 0.3–2.5 mg/L 1–3 h after an oral dose of 15 mg/kg body weight. Peak levels following intramuscular treatment at 7.5 mg/kg generally do not exceed 0.15 mg/L. It is extensively metabolized to biologically inactive 6-carboxylic and 2-carboxylic acid derivatives, which are excreted in the urine, mostly within 12 h.

• Clinical Use

  1,2,3,4-Tetrahydro-2-[(isopropylamino)methyl]-7-nitro-6-quinolinemethanol (Vansil) is an antischistosomal agent thatis indicated for the treatment of Schistosoma mansoni (intestinalschistosomiasis) infection. It has been shown to inhibitDNA, RNA, and protein synthesis in schistosomes. The6-hydroxymethyl group is critical for activity; metabolic activationof precursor 6-methyl derivatives is critical. Theoral bioavailability of oxamniquine is good; effectiveplasma levels are achieved in 1 to 1.5 hours. The plasmahalf-life is 1 to 2.5 hours. The drug is extensively metabolizedto inactive metabolites, of which the principal one isthe 6-carboxy derivative.
  The free base occurs as a yellow crystalline solid thatis slightly soluble in water but soluble in dilute aqueousmineral acids and soluble in most organic solvents. Itis available in capsules containing 250 mg of the drug.Oxamniquine is generally well tolerated. Dizziness anddrowsiness are common, but transitory, side effects. Seriousreactions, such as epileptiform convulsions, are rare.

• Clinical Use

  Infection with S. mansoni

• Nebenwirkungen

  Dizziness, sleepiness, nausea and headache occur frequently. Other side effects are probably due to the death and disintegration of the worms in the liver. Following treatment, urine may become red.

• Sicherheitsprofil

  Poison by ingestion, intraperitoneal and intramuscular routes. Human mutation data reported. An antischistosomal agent. When heated to decomposition it emits toxic fumes of NOx.

OXAMNIQUINE(200MG)DISCONTINUED Upstream-Materialien And Downstream Produkte

Oxamnichin Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global(23)Suppliers

21738-42-1, OXAMNIQUINE(200MG)DISCONTINUED Verwandte Suche: